Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Helius Medical Technologies Inc HSDT

Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.


NDAQ:HSDT - Post by User

Comment by Dividendspayon Apr 14, 2019 11:22pm
112 Views
Post# 29625956

RE:RE:RE:RE:RE:Trying to answer some of your questions

RE:RE:RE:RE:RE:Trying to answer some of your questions Frznth,
Thank-you for your thoughts.
I do not post often, but think deeply about equities, and will accordingly take a major position when I am convinced, as a long only investor.
The point in bringing back the thread, was to educate and shine a light on the analysis and thinking patterns,
This can improve our abilities as investors.
I stood alone in the debate, and left the board to the promoters.
I could see that my opinion wasn’t favoured, and I am not a “basher” so I left the room.
I didn’t come back to boast, but again to ask folks to reread the debate and carefully think about what was said, as it can improve your skill as an independent investor.
If you reread the entire debate and analyze the FDA papers, I believe you will see that evidence and the scientific approach to data, is important and profitable.

To me it is clear:if you use evidence to support your decisions, you have a higher probability of success.
When someone uses emotion or persuasion to make a point, go back to the data, and interpret the data with a rigorous framework.
I was able to be financially independent at a young age doing this, although I still choose to work.
why should you care?
Your questions now, relate directly to this approach.
I can give you my opinions on the path forward with  HSM but to be honest, it will take me several weeks to analyze all the information, and decide, as I need to review all the documents from the FDA, EMEA, and Australian authorities, and put it in context.
I could give you a quick gut reaction, but that would have a lower probability of success.

To me, I haven’t committed any capital to this company as I stated in the earlier thread, but I haven’t given up yet.

There may be a play yet.


Bullboard Posts